PCA3 and adenocarcinoma: We found that neratinib as a single agent displayed IC50 values that were 14–16-fold lower in NEPC PDOs OWCM154 and OWCM155 when compared with a CRPC adenocarcinoma PDO MSK-PCA3 (Fig. 8a).